Market Place
Sourcing Support
KalVista Presents Sebetralstat Data at Allergy Congress 2024
28 Oct 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals To Present At ACAAI Annual Meeting
18 Oct 2024 //
BUSINESSWIRE
KalVista Presents Sebetralstat Data At HAEi Global Forum
04 Oct 2024 //
BUSINESSWIRE
KalVista Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
02 Oct 2024 //
BUSINESSWIRE
KalVista Submit Additional Marketing Application For Sebetralstat
30 Sep 2024 //
BUSINESSWIRE
KalVista To Present Nine Abstracts At HAEi GAF
26 Sep 2024 //
BUSINESSWIRE
KalVista Appoints Brian Piekos as Chief Financial Officer
10 Sep 2024 //
BUSINESSWIRE
KalVista To Join Cantor Global Healthcare Conference
10 Sep 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
06 Sep 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Fiscal Q1 Results and Operational Update
05 Sep 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
04 Sep 2024 //
BUSINESSWIRE
KalVista Announces FDA Acceptance of Sebetralstat for Hereditary Angioedema
03 Sep 2024 //
BUSINESSWIRE
KalVista To Present Six Abstracts At 2024 Bradykinin Symposium
29 Aug 2024 //
BUSINESSWIRE
KalVista’s Sebetralstat Application Validated By European Medicines Agency
15 Aug 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Inducement Grants
02 Aug 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Provides Operational And Fiscal Year Update
11 Jul 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Jul 2024 //
BUSINESSWIRE
KalVista Initiates KONFIDENT-KID Trial for Treatment Hereditary Angioedema
27 Jun 2024 //
BUSINESSWIRE
KalVista Submits NDA To FDA For Sebetralstat as Oral Treatment Angioedema
18 Jun 2024 //
BUSINESSWIRE
KalVista files first oral on-demand HAE drug with FDA
18 Jun 2024 //
PHARMAPHORUM
KalVista Presents Data At Allergy, Dermatology Conferences
06 Jun 2024 //
BUSINESSWIRE
KalVista: Reports Nasdaq Inducement Grants
04 Jun 2024 //
BUSINESSWIRE
KalVista Presents Unmet Needs Data In Hereditary Angioedema At EAACI
03 Jun 2024 //
BUSINESSWIRE
KalVista Oral Sebetralstat Phase 3 Data In NEJM For Hereditary Angioedema
31 May 2024 //
BUSINESSWIRE
Kalvista Eaaci 2024 Abstracts: Ten Presentations At Allergy Congress
24 May 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
21 May 2024 //
BUSINESSWIRE
KalVista Reports Nasdaq Listing Rule Inducement Grants
02 May 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
01 May 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
22 Apr 2024 //
BUSINESSWIRE
KalVista to Present at 23rd Annual Needham Virtual Healthcare Conference
03 Apr 2024 //
BUSINESSWIRE
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
BUSINESSWIRE
KalVista Presents Data on Burden of Treatment and HAE Attack Journey
18 Mar 2024 //
BUSINESSWIRE
KalVista Awarded UK PIM Designation for Sebetralstat
12 Mar 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
11 Mar 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals to Present HAE Attack Journey Data
08 Mar 2024 //
BUSINESSWIRE
KalVista Announces Appointment of Benjamin L. Palleiko as CEO
07 Mar 2024 //
BUSINESSWIRE
KalVista to Participate in the Leerink Partners 2024 Biopharma Conference
06 Mar 2024 //
BUSINESSWIRE
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2024 //
BUSINESSWIRE
KalVista Presents Data on Unmet Needs in HAE from a Patient Perspective
27 Feb 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data
26 Feb 2024 //
BUSINESSWIRE
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
20 Feb 2024 //
BUSINESSWIRE
This Insider Has Just Sold Shares In KalVista Pharmaceuticals
18 Feb 2024 //
SIMPLYWALL
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data
16 Feb 2024 //
BUSINESSWIRE
KalVista Announces Pricing of a $160.1M Public Offering of Common Stock
15 Feb 2024 //
PRESS RELEASE
KalVista Announces Proposed Public Offering of Common Stock
14 Feb 2024 //
BUSINESSWIRE
KalVista reports PhIII success of angioedema drug
13 Feb 2024 //
ENDPTS
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
BUSINESSWIRE
KalVista Announces Publication of First Oral Factor XIIa Data in Pharmacology
20 Dec 2023 //
BUSINESSWIRE
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
07 Dec 2023 //
BUSINESSWIRE
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2023 //
BUSINESSWIRE
KalVista Presents Real-World Data at the 2023 Annual Scientific Meeting
14 Nov 2023 //
BUSINESSWIRE
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
13 Nov 2023 //
BUSINESSWIRE
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
07 Nov 2023 //
BUSINESSWIRE
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2023 //
BUSINESSWIRE
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting
02 Nov 2023 //
BUSINESSWIRE
KalVista Presents Data on HAE Attacks in Patients Receiving Prophylaxis
24 Oct 2023 //
BUSINESSWIRE
KalVista Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
BUSINESSWIRE
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
19 Sep 2023 //
BUSINESSWIRE
KalVista Reports First Fiscal Quarter Results and Provides Operational Update
07 Sep 2023 //
BUSINESSWIRE
KalVista Pharma to Present HAE Attack Journey Data at 2023 HAEi Regional EMEA
28 Aug 2023 //
BUSINESSWIRE
